カテゴリ： GlobalInfoResearch, 世界, 医療/バイオ

世界の過活動性膀胱診断及び治療法市場2022年：市場規模予測（～2028年）

■ 英語タイトル：Global Overactive Bladder Diagnosis and Treatment Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028

調査会社GlobalInfoResearch社が発行したリサーチレポート（データ管理コード：GIR22NO19502）■ 発行会社/調査会社：GlobalInfoResearch
■ 商品コード：GIR22NO19502
■ 発行日：2022年11月（※2025年版があります。お問い合わせください。）
■ 調査対象地域：グローバル
■ 産業分野：医薬品
■ ページ数：110
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（注文後2-3日）
■ 販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,480 ⇒換算￥528,960見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD5,220 ⇒換算￥793,440見積依頼/購入/質問フォーム
Corporate User（同一法人内共有可）USD6,960 ⇒換算￥1,057,920見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※GlobalInfoResearch社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[世界の過活動性膀胱診断及び治療法市場2022年：市場規模予測（～2028年）]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

過活動性膀胱診断及び治療法市場レポートは、世界の市場規模、地域および国レベルの市場規模、セグメント市場の成長性、市場シェア、競争環境、販売分析、国内および世界の市場プレーヤーの影響、バリューチェーンの最適化、最近の動向、機会分析、市場成長の戦略的な分析、製品発売、地域市場の拡大などに関する情報を提供します。
GlobalInfoResearchの最新の調査によると、世界の過活動性膀胱診断及び治療法の市場規模は2021年のxxx米ドルから2028年にはxxx米ドルと推定され、xxx％の成長率で成長すると予想されます。

過活動性膀胱診断及び治療法市場は種類と用途によって区分されます。2017年～2028年において、量と金額の観点から種類別および用途別セグメントの売上予測データを提供します。この分析は、適格なニッチ市場をターゲットにすることでビジネスを拡大するのに役立ちます。

種類別セグメントは次をカバーします。
・抗コリン薬、ミラベグロン、BOTOX、ニューロモデュレーション、その他

用途別セグメントは次のように区分されます。
・特発性過活動膀胱、神経原性過活動膀胱

世界の過活動性膀胱診断及び治療法市場の主要な市場プレーヤーは以下のとおりです。
・Astellas Pharma Inc、Teva Pharmaceutical Industries、Pfizer Inc、Abbvie Inc、Viatris Inc、Hisamitsu Pharmaceutical、Johnson & Johnson Services、Endo Pharmaceuticals、Lupin、KYORIN Pharmaceutical、Amneal Pharmaceuticals、Sun Pharmaceutical Industries、Glenmark、Macleods Pharmaceuticals、Medtronic、Ajanta Pharma、Granules India、Urovant Sciences、Apotex Inc.

地域別セグメントは次の地域・国をカバーします。
・北米（米国、カナダ、メキシコ）
・ヨーロッパ（ドイツ、フランス、イギリス、ロシア、イタリア）
・アジア太平洋（日本、中国、韓国、インド、東南アジア、オーストラリア）
・南アメリカ（ブラジル、アルゼンチン、コロンビア）
・中東およびアフリカ（サウジアラビア、UAE、エジプト、南アフリカ）

本調査レポートの内容は計15章あります。
・第1章では、過活動性膀胱診断及び治療法製品の調査範囲、市場の概要、市場の成長要因・阻害要因、および市場動向について説明します。
・第2章では、主要な過活動性膀胱診断及び治療法メーカーの企業概要、2019年～2022年までの過活動性膀胱診断及び治療法の価格、販売量、売上、市場シェアを掲載しています。
・第3章では、主要な過活動性膀胱診断及び治療法メーカーの競争状況、販売量、売上、世界市場シェアが重点的に比較分析されています。
・第4章では、2017年～2028年までの地域別過活動性膀胱診断及び治療法の販売量、売上、成長性を示しています。
・第5、6章では、2017年～2028年までの過活動性膀胱診断及び治療法の種類別と用途別の市場規模、市場シェアと成長率を掲載しています。
・第7、8、9、10、11章では、2017年～2022年までの世界の主要国での販売量、売上、市場シェア、並びに2023年～2028年までの主要地域での過活動性膀胱診断及び治療法市場予測を収録しています。
・第12章では、主要な原材料、主要なサプライヤー、および過活動性膀胱診断及び治療法の産業チェーンを掲載しています。
・第13、14、15章では、過活動性膀胱診断及び治療法の販売チャネル、販売業者、顧客、調査結果と結論、付録、データソースなどについて説明します。

***** 目次(一部) *****

・市場概要
- 過活動性膀胱診断及び治療法の概要
- 種類別分析（2017年vs2021年vs2028年）：抗コリン薬、ミラベグロン、BOTOX、ニューロモデュレーション、その他
- 用途別分析（2017年vs2021年vs2028年）：特発性過活動膀胱、神経原性過活動膀胱
- 世界の過活動性膀胱診断及び治療法市場規模・予測
- 世界の過活動性膀胱診断及び治療法生産能力分析
- 市場の成長要因・阻害要因・動向
・メーカー情報（企業概要、製品概要、販売量、価格、売上）
- Astellas Pharma Inc、Teva Pharmaceutical Industries、Pfizer Inc、Abbvie Inc、Viatris Inc、Hisamitsu Pharmaceutical、Johnson & Johnson Services、Endo Pharmaceuticals、Lupin、KYORIN Pharmaceutical、Amneal Pharmaceuticals、Sun Pharmaceutical Industries、Glenmark、Macleods Pharmaceuticals、Medtronic、Ajanta Pharma、Granules India、Urovant Sciences、Apotex Inc.
・メーカー別市場シェア・市場集中度
・地域別市場分析2017年-2028年
・種類別分析2017年-2028年：抗コリン薬、ミラベグロン、BOTOX、ニューロモデュレーション、その他
・用途別分析2017年-2028年：特発性過活動膀胱、神経原性過活動膀胱
・過活動性膀胱診断及び治療法の北米市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：アメリカ、カナダ、メキシコなど
・過活動性膀胱診断及び治療法のヨーロッパ市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：ドイツ、イギリス、フランス、ロシア、イタリアなど
・過活動性膀胱診断及び治療法のアジア市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：中国、日本、韓国、インド、東南アジア、オーストラリアなど
・過活動性膀胱診断及び治療法の南米市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：ブラジル、アルゼンチンなど
・過活動性膀胱診断及び治療法の中東・アフリカ市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：サウジアラビア、トルコ、エジプト、南アフリカなど
・原材料および産業チェーン
・販売チャネル、流通業者・代理店、顧客リスト
・調査の結果・結論

The Overactive Bladder Diagnosis and Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Overactive Bladder Diagnosis and Treatment market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during forecast period 2022-2028. Idiopathic Overactive Bladder accounting for % of the Overactive Bladder Diagnosis and Treatment global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Anticholinergics segment is altered to a % CAGR between 2022 and 2028.
Global key manufacturers of Overactive Bladder Diagnosis and Treatment include Astellas Pharma Inc, Teva Pharmaceutical Industries, Pfizer Inc, Abbvie Inc, and Viatris Inc, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Overactive Bladder Diagnosis and Treatment market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Anticholinergics
Mirabegron
BOTOX
Neuromodulation
Others
Market segment by Application can be divided into
Idiopathic Overactive Bladder
Neurogenic Overactive Bladder
The key market players for global Overactive Bladder Diagnosis and Treatment market are listed below:
Astellas Pharma Inc
Teva Pharmaceutical Industries
Pfizer Inc
Abbvie Inc
Viatris Inc
Hisamitsu Pharmaceutical
Johnson & Johnson Services
Endo Pharmaceuticals
Lupin
KYORIN Pharmaceutical
Amneal Pharmaceuticals
Sun Pharmaceutical Industries
Glenmark
Macleods Pharmaceuticals
Medtronic
Ajanta Pharma
Granules India
Urovant Sciences
Apotex Inc.
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Overactive Bladder Diagnosis and Treatment product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Overactive Bladder Diagnosis and Treatment, with price, sales, revenue and global market share of Overactive Bladder Diagnosis and Treatment from 2019 to 2022.
Chapter 3, the Overactive Bladder Diagnosis and Treatment competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Overactive Bladder Diagnosis and Treatment breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2017 to 2028.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2017 to 2022.and Overactive Bladder Diagnosis and Treatment market forecast, by regions, type and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of Overactive Bladder Diagnosis and Treatment.
Chapter 13, 14, and 15, to describe Overactive Bladder Diagnosis and Treatment sales channel, distributors, customers, research findings and conclusion, appendix and data source.

*** レポート目次（コンテンツ）***

1 Market Overview
1.1 Overactive Bladder Diagnosis and Treatment Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Overactive Bladder Diagnosis and Treatment Revenue by Type: 2017 Versus 2021 Versus 2028
1.2.2 Anticholinergics
1.2.3 Mirabegron
1.2.4 BOTOX
1.2.5 Neuromodulation
1.2.6 Others
1.3 Market Analysis by Application
1.3.1 Overview: Global Overactive Bladder Diagnosis and Treatment Revenue by Application: 2017 Versus 2021 Versus 2028
1.3.2 Idiopathic Overactive Bladder
1.3.3 Neurogenic Overactive Bladder
1.4 Global Overactive Bladder Diagnosis and Treatment Market Size & Forecast
1.4.1 Global Overactive Bladder Diagnosis and Treatment Sales in Value (2017 & 2021 & 2028)
1.4.2 Global Overactive Bladder Diagnosis and Treatment Sales in Volume (2017-2028)
1.4.3 Global Overactive Bladder Diagnosis and Treatment Price (2017-2028)
1.5 Global Overactive Bladder Diagnosis and Treatment Production Capacity Analysis
1.5.1 Global Overactive Bladder Diagnosis and Treatment Total Production Capacity (2017-2028)
1.5.2 Global Overactive Bladder Diagnosis and Treatment Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Overactive Bladder Diagnosis and Treatment Market Drivers
1.6.2 Overactive Bladder Diagnosis and Treatment Market Restraints
1.6.3 Overactive Bladder Diagnosis and Treatment Trends Analysis
2 Manufacturers Profiles
2.1 Astellas Pharma Inc
2.1.1 Astellas Pharma Inc Details
2.1.2 Astellas Pharma Inc Major Business
2.1.3 Astellas Pharma Inc Overactive Bladder Diagnosis and Treatment Product and Services
2.1.4 Astellas Pharma Inc Overactive Bladder Diagnosis and Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2 Teva Pharmaceutical Industries
2.2.1 Teva Pharmaceutical Industries Details
2.2.2 Teva Pharmaceutical Industries Major Business
2.2.3 Teva Pharmaceutical Industries Overactive Bladder Diagnosis and Treatment Product and Services
2.2.4 Teva Pharmaceutical Industries Overactive Bladder Diagnosis and Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3 Pfizer Inc
2.3.1 Pfizer Inc Details
2.3.2 Pfizer Inc Major Business
2.3.3 Pfizer Inc Overactive Bladder Diagnosis and Treatment Product and Services
2.3.4 Pfizer Inc Overactive Bladder Diagnosis and Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4 Abbvie Inc
2.4.1 Abbvie Inc Details
2.4.2 Abbvie Inc Major Business
2.4.3 Abbvie Inc Overactive Bladder Diagnosis and Treatment Product and Services
2.4.4 Abbvie Inc Overactive Bladder Diagnosis and Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5 Viatris Inc
2.5.1 Viatris Inc Details
2.5.2 Viatris Inc Major Business
2.5.3 Viatris Inc Overactive Bladder Diagnosis and Treatment Product and Services
2.5.4 Viatris Inc Overactive Bladder Diagnosis and Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6 Hisamitsu Pharmaceutical
2.6.1 Hisamitsu Pharmaceutical Details
2.6.2 Hisamitsu Pharmaceutical Major Business
2.6.3 Hisamitsu Pharmaceutical Overactive Bladder Diagnosis and Treatment Product and Services
2.6.4 Hisamitsu Pharmaceutical Overactive Bladder Diagnosis and Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7 Johnson & Johnson Services
2.7.1 Johnson & Johnson Services Details
2.7.2 Johnson & Johnson Services Major Business
2.7.3 Johnson & Johnson Services Overactive Bladder Diagnosis and Treatment Product and Services
2.7.4 Johnson & Johnson Services Overactive Bladder Diagnosis and Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8 Endo Pharmaceuticals
2.8.1 Endo Pharmaceuticals Details
2.8.2 Endo Pharmaceuticals Major Business
2.8.3 Endo Pharmaceuticals Overactive Bladder Diagnosis and Treatment Product and Services
2.8.4 Endo Pharmaceuticals Overactive Bladder Diagnosis and Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.9 Lupin
2.9.1 Lupin Details
2.9.2 Lupin Major Business
2.9.3 Lupin Overactive Bladder Diagnosis and Treatment Product and Services
2.9.4 Lupin Overactive Bladder Diagnosis and Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.10 KYORIN Pharmaceutical
2.10.1 KYORIN Pharmaceutical Details
2.10.2 KYORIN Pharmaceutical Major Business
2.10.3 KYORIN Pharmaceutical Overactive Bladder Diagnosis and Treatment Product and Services
2.10.4 KYORIN Pharmaceutical Overactive Bladder Diagnosis and Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.11 Amneal Pharmaceuticals
2.11.1 Amneal Pharmaceuticals Details
2.11.2 Amneal Pharmaceuticals Major Business
2.11.3 Amneal Pharmaceuticals Overactive Bladder Diagnosis and Treatment Product and Services
2.11.4 Amneal Pharmaceuticals Overactive Bladder Diagnosis and Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.12 Sun Pharmaceutical Industries
2.12.1 Sun Pharmaceutical Industries Details
2.12.2 Sun Pharmaceutical Industries Major Business
2.12.3 Sun Pharmaceutical Industries Overactive Bladder Diagnosis and Treatment Product and Services
2.12.4 Sun Pharmaceutical Industries Overactive Bladder Diagnosis and Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.13 Glenmark
2.13.1 Glenmark Details
2.13.2 Glenmark Major Business
2.13.3 Glenmark Overactive Bladder Diagnosis and Treatment Product and Services
2.13.4 Glenmark Overactive Bladder Diagnosis and Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.14 Macleods Pharmaceuticals
2.14.1 Macleods Pharmaceuticals Details
2.14.2 Macleods Pharmaceuticals Major Business
2.14.3 Macleods Pharmaceuticals Overactive Bladder Diagnosis and Treatment Product and Services
2.14.4 Macleods Pharmaceuticals Overactive Bladder Diagnosis and Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.15 Medtronic
2.15.1 Medtronic Details
2.15.2 Medtronic Major Business
2.15.3 Medtronic Overactive Bladder Diagnosis and Treatment Product and Services
2.15.4 Medtronic Overactive Bladder Diagnosis and Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.16 Ajanta Pharma
2.16.1 Ajanta Pharma Details
2.16.2 Ajanta Pharma Major Business
2.16.3 Ajanta Pharma Overactive Bladder Diagnosis and Treatment Product and Services
2.16.4 Ajanta Pharma Overactive Bladder Diagnosis and Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.17 Granules India
2.17.1 Granules India Details
2.17.2 Granules India Major Business
2.17.3 Granules India Overactive Bladder Diagnosis and Treatment Product and Services
2.17.4 Granules India Overactive Bladder Diagnosis and Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.18 Urovant Sciences
2.18.1 Urovant Sciences Details
2.18.2 Urovant Sciences Major Business
2.18.3 Urovant Sciences Overactive Bladder Diagnosis and Treatment Product and Services
2.18.4 Urovant Sciences Overactive Bladder Diagnosis and Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.19 Apotex Inc.
2.19.1 Apotex Inc. Details
2.19.2 Apotex Inc. Major Business
2.19.3 Apotex Inc. Overactive Bladder Diagnosis and Treatment Product and Services
2.19.4 Apotex Inc. Overactive Bladder Diagnosis and Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
3 Overactive Bladder Diagnosis and Treatment Breakdown Data by Manufacturer
3.1 Global Overactive Bladder Diagnosis and Treatment Sales in Volume by Manufacturer (2019, 2020, 2021, and 2022)
3.2 Global Overactive Bladder Diagnosis and Treatment Revenue by Manufacturer (2019, 2020, 2021, and 2022)
3.3 Key Manufacturer Market Position in Overactive Bladder Diagnosis and Treatment
3.4 Market Concentration Rate
3.4.1 Top 3 Overactive Bladder Diagnosis and Treatment Manufacturer Market Share in 2021
3.4.2 Top 6 Overactive Bladder Diagnosis and Treatment Manufacturer Market Share in 2021
3.5 Global Overactive Bladder Diagnosis and Treatment Production Capacity by Company: 2021 VS 2022
3.6 Manufacturer by Geography: Head Office and Overactive Bladder Diagnosis and Treatment Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Overactive Bladder Diagnosis and Treatment Market Size by Region
4.1.1 Global Overactive Bladder Diagnosis and Treatment Sales in Volume by Region (2017-2028)
4.1.2 Global Overactive Bladder Diagnosis and Treatment Revenue by Region (2017-2028)
4.2 North America Overactive Bladder Diagnosis and Treatment Revenue (2017-2028)
4.3 Europe Overactive Bladder Diagnosis and Treatment Revenue (2017-2028)
4.4 Asia-Pacific Overactive Bladder Diagnosis and Treatment Revenue (2017-2028)
4.5 South America Overactive Bladder Diagnosis and Treatment Revenue (2017-2028)
4.6 Middle East and Africa Overactive Bladder Diagnosis and Treatment Revenue (2017-2028)
5 Market Segment by Type
5.1 Global Overactive Bladder Diagnosis and Treatment Sales in Volume by Type (2017-2028)
5.2 Global Overactive Bladder Diagnosis and Treatment Revenue by Type (2017-2028)
5.3 Global Overactive Bladder Diagnosis and Treatment Price by Type (2017-2028)
6 Market Segment by Application
6.1 Global Overactive Bladder Diagnosis and Treatment Sales in Volume by Application (2017-2028)
6.2 Global Overactive Bladder Diagnosis and Treatment Revenue by Application (2017-2028)
6.3 Global Overactive Bladder Diagnosis and Treatment Price by Application (2017-2028)
7 North America by Country, by Type, and by Application
7.1 North America Overactive Bladder Diagnosis and Treatment Sales by Type (2017-2028)
7.2 North America Overactive Bladder Diagnosis and Treatment Sales by Application (2017-2028)
7.3 North America Overactive Bladder Diagnosis and Treatment Market Size by Country
7.3.1 North America Overactive Bladder Diagnosis and Treatment Sales in Volume by Country (2017-2028)
7.3.2 North America Overactive Bladder Diagnosis and Treatment Revenue by Country (2017-2028)
7.3.3 United States Market Size and Forecast (2017-2028)
7.3.4 Canada Market Size and Forecast (2017-2028)
7.3.5 Mexico Market Size and Forecast (2017-2028)
8 Europe by Country, by Type, and by Application
8.1 Europe Overactive Bladder Diagnosis and Treatment Sales by Type (2017-2028)
8.2 Europe Overactive Bladder Diagnosis and Treatment Sales by Application (2017-2028)
8.3 Europe Overactive Bladder Diagnosis and Treatment Market Size by Country
8.3.1 Europe Overactive Bladder Diagnosis and Treatment Sales in Volume by Country (2017-2028)
8.3.2 Europe Overactive Bladder Diagnosis and Treatment Revenue by Country (2017-2028)
8.3.3 Germany Market Size and Forecast (2017-2028)
8.3.4 France Market Size and Forecast (2017-2028)
8.3.5 United Kingdom Market Size and Forecast (2017-2028)
8.3.6 Russia Market Size and Forecast (2017-2028)
8.3.7 Italy Market Size and Forecast (2017-2028)
9 Asia-Pacific by Region, by Type, and by Application
9.1 Asia-Pacific Overactive Bladder Diagnosis and Treatment Sales by Type (2017-2028)
9.2 Asia-Pacific Overactive Bladder Diagnosis and Treatment Sales by Application (2017-2028)
9.3 Asia-Pacific Overactive Bladder Diagnosis and Treatment Market Size by Region
9.3.1 Asia-Pacific Overactive Bladder Diagnosis and Treatment Sales in Volume by Region (2017-2028)
9.3.2 Asia-Pacific Overactive Bladder Diagnosis and Treatment Revenue by Region (2017-2028)
9.3.3 China Market Size and Forecast (2017-2028)
9.3.4 Japan Market Size and Forecast (2017-2028)
9.3.5 Korea Market Size and Forecast (2017-2028)
9.3.6 India Market Size and Forecast (2017-2028)
9.3.7 Southeast Asia Market Size and Forecast (2017-2028)
9.3.8 Australia Market Size and Forecast (2017-2028)
10 South America by Region, by Type, and by Application
10.1 South America Overactive Bladder Diagnosis and Treatment Sales by Type (2017-2028)
10.2 South America Overactive Bladder Diagnosis and Treatment Sales by Application (2017-2028)
10.3 South America Overactive Bladder Diagnosis and Treatment Market Size by Country
10.3.1 South America Overactive Bladder Diagnosis and Treatment Sales in Volume by Country (2017-2028)
10.3.2 South America Overactive Bladder Diagnosis and Treatment Revenue by Country (2017-2028)
10.3.3 Brazil Market Size and Forecast (2017-2028)
10.3.4 Argentina Market Size and Forecast (2017-2028)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Overactive Bladder Diagnosis and Treatment Sales by Type (2017-2028)
11.2 Middle East & Africa Overactive Bladder Diagnosis and Treatment Sales by Application (2017-2028)
11.3 Middle East & Africa Overactive Bladder Diagnosis and Treatment Market Size by Country
11.3.1 Middle East & Africa Overactive Bladder Diagnosis and Treatment Sales in Volume by Country (2017-2028)
11.3.2 Middle East & Africa Overactive Bladder Diagnosis and Treatment Revenue by Country (2017-2028)
11.3.3 Turkey Market Size and Forecast (2017-2028)
11.3.4 Egypt Market Size and Forecast (2017-2028)
11.3.5 Saudi Arabia Market Size and Forecast (2017-2028)
11.3.6 South Africa Market Size and Forecast (2017-2028)
12 Raw Material and Industry Chain
12.1 Raw Material of Overactive Bladder Diagnosis and Treatment and Key Manufacturers
12.2 Manufacturing Costs Percentage of Overactive Bladder Diagnosis and Treatment
12.3 Overactive Bladder Diagnosis and Treatment Production Process
12.4 Overactive Bladder Diagnosis and Treatment Industrial Chain
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Overactive Bladder Diagnosis and Treatment Typical Distributors
13.3 Overactive Bladder Diagnosis and Treatment Typical Customers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Research Process and Data Source
15.3 Disclaimer

List of Tables
Table 1. Global Overactive Bladder Diagnosis and Treatment Revenue by Type, (USD Million), 2017 & 2021 & 2028
Table 2. Global Overactive Bladder Diagnosis and Treatment Revenue by Application, (USD Million), 2017 & 2021 & 2028
Table 3. Astellas Pharma Inc Basic Information, Manufacturing Base and Competitors
Table 4. Astellas Pharma Inc Major Business
Table 5. Astellas Pharma Inc Overactive Bladder Diagnosis and Treatment Product and Services
Table 6. Astellas Pharma Inc Overactive Bladder Diagnosis and Treatment Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 7. Teva Pharmaceutical Industries Basic Information, Manufacturing Base and Competitors
Table 8. Teva Pharmaceutical Industries Major Business
Table 9. Teva Pharmaceutical Industries Overactive Bladder Diagnosis and Treatment Product and Services
Table 10. Teva Pharmaceutical Industries Overactive Bladder Diagnosis and Treatment Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 11. Pfizer Inc Basic Information, Manufacturing Base and Competitors
Table 12. Pfizer Inc Major Business
Table 13. Pfizer Inc Overactive Bladder Diagnosis and Treatment Product and Services
Table 14. Pfizer Inc Overactive Bladder Diagnosis and Treatment Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 15. Abbvie Inc Basic Information, Manufacturing Base and Competitors
Table 16. Abbvie Inc Major Business
Table 17. Abbvie Inc Overactive Bladder Diagnosis and Treatment Product and Services
Table 18. Abbvie Inc Overactive Bladder Diagnosis and Treatment Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 19. Viatris Inc Basic Information, Manufacturing Base and Competitors
Table 20. Viatris Inc Major Business
Table 21. Viatris Inc Overactive Bladder Diagnosis and Treatment Product and Services
Table 22. Viatris Inc Overactive Bladder Diagnosis and Treatment Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 23. Hisamitsu Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 24. Hisamitsu Pharmaceutical Major Business
Table 25. Hisamitsu Pharmaceutical Overactive Bladder Diagnosis and Treatment Product and Services
Table 26. Hisamitsu Pharmaceutical Overactive Bladder Diagnosis and Treatment Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 27. Johnson & Johnson Services Basic Information, Manufacturing Base and Competitors
Table 28. Johnson & Johnson Services Major Business
Table 29. Johnson & Johnson Services Overactive Bladder Diagnosis and Treatment Product and Services
Table 30. Johnson & Johnson Services Overactive Bladder Diagnosis and Treatment Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 31. Endo Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 32. Endo Pharmaceuticals Major Business
Table 33. Endo Pharmaceuticals Overactive Bladder Diagnosis and Treatment Product and Services
Table 34. Endo Pharmaceuticals Overactive Bladder Diagnosis and Treatment Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 35. Lupin Basic Information, Manufacturing Base and Competitors
Table 36. Lupin Major Business
Table 37. Lupin Overactive Bladder Diagnosis and Treatment Product and Services
Table 38. Lupin Overactive Bladder Diagnosis and Treatment Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 39. KYORIN Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 40. KYORIN Pharmaceutical Major Business
Table 41. KYORIN Pharmaceutical Overactive Bladder Diagnosis and Treatment Product and Services
Table 42. KYORIN Pharmaceutical Overactive Bladder Diagnosis and Treatment Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 43. Amneal Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 44. Amneal Pharmaceuticals Major Business
Table 45. Amneal Pharmaceuticals Overactive Bladder Diagnosis and Treatment Product and Services
Table 46. Amneal Pharmaceuticals Overactive Bladder Diagnosis and Treatment Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 47. Sun Pharmaceutical Industries Basic Information, Manufacturing Base and Competitors
Table 48. Sun Pharmaceutical Industries Major Business
Table 49. Sun Pharmaceutical Industries Overactive Bladder Diagnosis and Treatment Product and Services
Table 50. Sun Pharmaceutical Industries Overactive Bladder Diagnosis and Treatment Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 51. Glenmark Basic Information, Manufacturing Base and Competitors
Table 52. Glenmark Major Business
Table 53. Glenmark Overactive Bladder Diagnosis and Treatment Product and Services
Table 54. Glenmark Overactive Bladder Diagnosis and Treatment Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 55. Macleods Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 56. Macleods Pharmaceuticals Major Business
Table 57. Macleods Pharmaceuticals Overactive Bladder Diagnosis and Treatment Product and Services
Table 58. Macleods Pharmaceuticals Overactive Bladder Diagnosis and Treatment Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 59. Medtronic Basic Information, Manufacturing Base and Competitors
Table 60. Medtronic Major Business
Table 61. Medtronic Overactive Bladder Diagnosis and Treatment Product and Services
Table 62. Medtronic Overactive Bladder Diagnosis and Treatment Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 63. Ajanta Pharma Basic Information, Manufacturing Base and Competitors
Table 64. Ajanta Pharma Major Business
Table 65. Ajanta Pharma Overactive Bladder Diagnosis and Treatment Product and Services
Table 66. Ajanta Pharma Overactive Bladder Diagnosis and Treatment Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 67. Granules India Basic Information, Manufacturing Base and Competitors
Table 68. Granules India Major Business
Table 69. Granules India Overactive Bladder Diagnosis and Treatment Product and Services
Table 70. Granules India Overactive Bladder Diagnosis and Treatment Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 71. Urovant Sciences Basic Information, Manufacturing Base and Competitors
Table 72. Urovant Sciences Major Business
Table 73. Urovant Sciences Overactive Bladder Diagnosis and Treatment Product and Services
Table 74. Urovant Sciences Overactive Bladder Diagnosis and Treatment Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 75. Apotex Inc. Basic Information, Manufacturing Base and Competitors
Table 76. Apotex Inc. Major Business
Table 77. Apotex Inc. Overactive Bladder Diagnosis and Treatment Product and Services
Table 78. Apotex Inc. Overactive Bladder Diagnosis and Treatment Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 79. Global Overactive Bladder Diagnosis and Treatment Sales by Manufacturer (2019, 2020, 2021, and 2022) & (K Units)
Table 80. Global Overactive Bladder Diagnosis and Treatment Revenue by Manufacturer (2019, 2020, 2021, and 2022) & (USD Million)
Table 81. Market Position of Manufacturers in Overactive Bladder Diagnosis and Treatment, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2021
Table 82. Global Overactive Bladder Diagnosis and Treatment Production Capacity by Company, (K Units): 2020 VS 2021
Table 83. Head Office and Overactive Bladder Diagnosis and Treatment Production Site of Key Manufacturer
Table 84. Overactive Bladder Diagnosis and Treatment New Entrant and Capacity Expansion Plans
Table 85. Overactive Bladder Diagnosis and Treatment Mergers & Acquisitions in the Past Five Years
Table 86. Global Overactive Bladder Diagnosis and Treatment Sales by Region (2017-2022) & (K Units)
Table 87. Global Overactive Bladder Diagnosis and Treatment Sales by Region (2023-2028) & (K Units)
Table 88. Global Overactive Bladder Diagnosis and Treatment Revenue by Region (2017-2022) & (USD Million)
Table 89. Global Overactive Bladder Diagnosis and Treatment Revenue by Region (2023-2028) & (USD Million)
Table 90. Global Overactive Bladder Diagnosis and Treatment Sales by Type (2017-2022) & (K Units)
Table 91. Global Overactive Bladder Diagnosis and Treatment Sales by Type (2023-2028) & (K Units)
Table 92. Global Overactive Bladder Diagnosis and Treatment Revenue by Type (2017-2022) & (USD Million)
Table 93. Global Overactive Bladder Diagnosis and Treatment Revenue by Type (2023-2028) & (USD Million)
Table 94. Global Overactive Bladder Diagnosis and Treatment Price by Type (2017-2022) & (US$/Unit)
Table 95. Global Overactive Bladder Diagnosis and Treatment Price by Type (2023-2028) & (US$/Unit)
Table 96. Global Overactive Bladder Diagnosis and Treatment Sales by Application (2017-2022) & (K Units)
Table 97. Global Overactive Bladder Diagnosis and Treatment Sales by Application (2023-2028) & (K Units)
Table 98. Global Overactive Bladder Diagnosis and Treatment Revenue by Application (2017-2022) & (USD Million)
Table 99. Global Overactive Bladder Diagnosis and Treatment Revenue by Application (2023-2028) & (USD Million)
Table 100. Global Overactive Bladder Diagnosis and Treatment Price by Application (2017-2022) & (US$/Unit)
Table 101. Global Overactive Bladder Diagnosis and Treatment Price by Application (2023-2028) & (US$/Unit)
Table 102. North America Overactive Bladder Diagnosis and Treatment Sales by Country (2017-2022) & (K Units)
Table 103. North America Overactive Bladder Diagnosis and Treatment Sales by Country (2023-2028) & (K Units)
Table 104. North America Overactive Bladder Diagnosis and Treatment Revenue by Country (2017-2022) & (USD Million)
Table 105. North America Overactive Bladder Diagnosis and Treatment Revenue by Country (2023-2028) & (USD Million)
Table 106. North America Overactive Bladder Diagnosis and Treatment Sales by Type (2017-2022) & (K Units)
Table 107. North America Overactive Bladder Diagnosis and Treatment Sales by Type (2023-2028) & (K Units)
Table 108. North America Overactive Bladder Diagnosis and Treatment Sales by Application (2017-2022) & (K Units)
Table 109. North America Overactive Bladder Diagnosis and Treatment Sales by Application (2023-2028) & (K Units)
Table 110. Europe Overactive Bladder Diagnosis and Treatment Sales by Country (2017-2022) & (K Units)
Table 111. Europe Overactive Bladder Diagnosis and Treatment Sales by Country (2023-2028) & (K Units)
Table 112. Europe Overactive Bladder Diagnosis and Treatment Revenue by Country (2017-2022) & (USD Million)
Table 113. Europe Overactive Bladder Diagnosis and Treatment Revenue by Country (2023-2028) & (USD Million)
Table 114. Europe Overactive Bladder Diagnosis and Treatment Sales by Type (2017-2022) & (K Units)
Table 115. Europe Overactive Bladder Diagnosis and Treatment Sales by Type (2023-2028) & (K Units)
Table 116. Europe Overactive Bladder Diagnosis and Treatment Sales by Application (2017-2022) & (K Units)
Table 117. Europe Overactive Bladder Diagnosis and Treatment Sales by Application (2023-2028) & (K Units)
Table 118. Asia-Pacific Overactive Bladder Diagnosis and Treatment Sales by Region (2017-2022) & (K Units)
Table 119. Asia-Pacific Overactive Bladder Diagnosis and Treatment Sales by Region (2023-2028) & (K Units)
Table 120. Asia-Pacific Overactive Bladder Diagnosis and Treatment Revenue by Region (2017-2022) & (USD Million)
Table 121. Asia-Pacific Overactive Bladder Diagnosis and Treatment Revenue by Region (2023-2028) & (USD Million)
Table 122. Asia-Pacific Overactive Bladder Diagnosis and Treatment Sales by Type (2017-2022) & (K Units)
Table 123. Asia-Pacific Overactive Bladder Diagnosis and Treatment Sales by Type (2023-2028) & (K Units)
Table 124. Asia-Pacific Overactive Bladder Diagnosis and Treatment Sales by Application (2017-2022) & (K Units)
Table 125. Asia-Pacific Overactive Bladder Diagnosis and Treatment Sales by Application (2023-2028) & (K Units)
Table 126. South America Overactive Bladder Diagnosis and Treatment Sales by Country (2017-2022) & (K Units)
Table 127. South America Overactive Bladder Diagnosis and Treatment Sales by Country (2023-2028) & (K Units)
Table 128. South America Overactive Bladder Diagnosis and Treatment Revenue by Country (2017-2022) & (USD Million)
Table 129. South America Overactive Bladder Diagnosis and Treatment Revenue by Country (2023-2028) & (USD Million)
Table 130. South America Overactive Bladder Diagnosis and Treatment Sales by Type (2017-2022) & (K Units)
Table 131. South America Overactive Bladder Diagnosis and Treatment Sales by Type (2023-2028) & (K Units)
Table 132. South America Overactive Bladder Diagnosis and Treatment Sales by Application (2017-2022) & (K Units)
Table 133. South America Overactive Bladder Diagnosis and Treatment Sales by Application (2023-2028) & (K Units)
Table 134. Middle East & Africa Overactive Bladder Diagnosis and Treatment Sales by Region (2017-2022) & (K Units)
Table 135. Middle East & Africa Overactive Bladder Diagnosis and Treatment Sales by Region (2023-2028) & (K Units)
Table 136. Middle East & Africa Overactive Bladder Diagnosis and Treatment Revenue by Region (2017-2022) & (USD Million)
Table 137. Middle East & Africa Overactive Bladder Diagnosis and Treatment Revenue by Region (2023-2028) & (USD Million)
Table 138. Middle East & Africa Overactive Bladder Diagnosis and Treatment Sales by Type (2017-2022) & (K Units)
Table 139. Middle East & Africa Overactive Bladder Diagnosis and Treatment Sales by Type (2023-2028) & (K Units)
Table 140. Middle East & Africa Overactive Bladder Diagnosis and Treatment Sales by Application (2017-2022) & (K Units)
Table 141. Middle East & Africa Overactive Bladder Diagnosis and Treatment Sales by Application (2023-2028) & (K Units)
Table 142. Overactive Bladder Diagnosis and Treatment Raw Material
Table 143. Key Manufacturers of Overactive Bladder Diagnosis and Treatment Raw Materials
Table 144. Direct Channel Pros & Cons
Table 145. Indirect Channel Pros & Cons
Table 146. Overactive Bladder Diagnosis and Treatment Typical Distributors
Table 147. Overactive Bladder Diagnosis and Treatment Typical Customers
List of Figures
Figure 1. Overactive Bladder Diagnosis and Treatment Picture
Figure 2. Global Overactive Bladder Diagnosis and Treatment Revenue Market Share by Type in 2021
Figure 3. Anticholinergics
Figure 4. Mirabegron
Figure 5. BOTOX
Figure 6. Neuromodulation
Figure 7. Others
Figure 8. Global Overactive Bladder Diagnosis and Treatment Revenue Market Share by Application in 2021
Figure 9. Idiopathic Overactive Bladder
Figure 10. Neurogenic Overactive Bladder
Figure 11. Global Overactive Bladder Diagnosis and Treatment Revenue, (USD Million) & (K Units): 2017 & 2021 & 2028
Figure 12. Global Overactive Bladder Diagnosis and Treatment Revenue and Forecast (2017-2028) & (USD Million)
Figure 13. Global Overactive Bladder Diagnosis and Treatment Sales (2017-2028) & (K Units)
Figure 14. Global Overactive Bladder Diagnosis and Treatment Price (2017-2028) & (US$/Unit)
Figure 15. Global Overactive Bladder Diagnosis and Treatment Production Capacity (2017-2028) & (K Units)
Figure 16. Global Overactive Bladder Diagnosis and Treatment Production Capacity by Geographic Region: 2022 VS 2028
Figure 17. Overactive Bladder Diagnosis and Treatment Market Drivers
Figure 18. Overactive Bladder Diagnosis and Treatment Market Restraints
Figure 19. Overactive Bladder Diagnosis and Treatment Market Trends
Figure 20. Global Overactive Bladder Diagnosis and Treatment Sales Market Share by Manufacturer in 2021
Figure 21. Global Overactive Bladder Diagnosis and Treatment Revenue Market Share by Manufacturer in 2021
Figure 22. Overactive Bladder Diagnosis and Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2021
Figure 23. Top 3 Overactive Bladder Diagnosis and Treatment Manufacturer (Revenue) Market Share in 2021
Figure 24. Top 6 Overactive Bladder Diagnosis and Treatment Manufacturer (Revenue) Market Share in 2021
Figure 25. Global Overactive Bladder Diagnosis and Treatment Sales Market Share by Region (2017-2028)
Figure 26. Global Overactive Bladder Diagnosis and Treatment Revenue Market Share by Region (2017-2028)
Figure 27. North America Overactive Bladder Diagnosis and Treatment Revenue (2017-2028) & (USD Million)
Figure 28. Europe Overactive Bladder Diagnosis and Treatment Revenue (2017-2028) & (USD Million)
Figure 29. Asia-Pacific Overactive Bladder Diagnosis and Treatment Revenue (2017-2028) & (USD Million)
Figure 30. South America Overactive Bladder Diagnosis and Treatment Revenue (2017-2028) & (USD Million)
Figure 31. Middle East & Africa Overactive Bladder Diagnosis and Treatment Revenue (2017-2028) & (USD Million)
Figure 32. Global Overactive Bladder Diagnosis and Treatment Sales Market Share by Type (2017-2028)
Figure 33. Global Overactive Bladder Diagnosis and Treatment Revenue Market Share by Type (2017-2028)
Figure 34. Global Overactive Bladder Diagnosis and Treatment Price by Type (2017-2028) & (US$/Unit)
Figure 35. Global Overactive Bladder Diagnosis and Treatment Sales Market Share by Application (2017-2028)
Figure 36. Global Overactive Bladder Diagnosis and Treatment Revenue Market Share by Application (2017-2028)
Figure 37. Global Overactive Bladder Diagnosis and Treatment Price by Application (2017-2028) & (US$/Unit)
Figure 38. North America Overactive Bladder Diagnosis and Treatment Sales Market Share by Type (2017-2028)
Figure 39. North America Overactive Bladder Diagnosis and Treatment Sales Market Share by Application (2017-2028)
Figure 40. North America Overactive Bladder Diagnosis and Treatment Sales Market Share by Country (2017-2028)
Figure 41. North America Overactive Bladder Diagnosis and Treatment Revenue Market Share by Country (2017-2028)
Figure 42. United States Overactive Bladder Diagnosis and Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 43. Canada Overactive Bladder Diagnosis and Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 44. Mexico Overactive Bladder Diagnosis and Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 45. Europe Overactive Bladder Diagnosis and Treatment Sales Market Share by Type (2017-2028)
Figure 46. Europe Overactive Bladder Diagnosis and Treatment Sales Market Share by Application (2017-2028)
Figure 47. Europe Overactive Bladder Diagnosis and Treatment Sales Market Share by Country (2017-2028)
Figure 48. Europe Overactive Bladder Diagnosis and Treatment Revenue Market Share by Country (2017-2028)
Figure 49. Germany Overactive Bladder Diagnosis and Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 50. France Overactive Bladder Diagnosis and Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 51. United Kingdom Overactive Bladder Diagnosis and Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 52. Russia Overactive Bladder Diagnosis and Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 53. Italy Overactive Bladder Diagnosis and Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 54. Asia-Pacific Overactive Bladder Diagnosis and Treatment Sales Market Share by Region (2017-2028)
Figure 55. Asia-Pacific Overactive Bladder Diagnosis and Treatment Sales Market Share by Application (2017-2028)
Figure 56. Asia-Pacific Overactive Bladder Diagnosis and Treatment Sales Market Share by Region (2017-2028)
Figure 57. Asia-Pacific Overactive Bladder Diagnosis and Treatment Revenue Market Share by Region (2017-2028)
Figure 58. China Overactive Bladder Diagnosis and Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 59. Japan Overactive Bladder Diagnosis and Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 60. Korea Overactive Bladder Diagnosis and Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 61. India Overactive Bladder Diagnosis and Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 62. Southeast Asia Overactive Bladder Diagnosis and Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 63. Australia Overactive Bladder Diagnosis and Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 64. South America Overactive Bladder Diagnosis and Treatment Sales Market Share by Type (2017-2028)
Figure 65. South America Overactive Bladder Diagnosis and Treatment Sales Market Share by Application (2017-2028)
Figure 66. South America Overactive Bladder Diagnosis and Treatment Sales Market Share by Country (2017-2028)
Figure 67. South America Overactive Bladder Diagnosis and Treatment Revenue Market Share by Country (2017-2028)
Figure 68. Brazil Overactive Bladder Diagnosis and Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 69. Argentina Overactive Bladder Diagnosis and Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 70. Middle East & Africa Overactive Bladder Diagnosis and Treatment Sales Market Share by Type (2017-2028)
Figure 71. Middle East & Africa Overactive Bladder Diagnosis and Treatment Sales Market Share by Application (2017-2028)
Figure 72. Middle East & Africa Overactive Bladder Diagnosis and Treatment Sales Market Share by Region (2017-2028)
Figure 73. Middle East & Africa Overactive Bladder Diagnosis and Treatment Revenue Market Share by Region (2017-2028)
Figure 74. Turkey Overactive Bladder Diagnosis and Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 75. Egypt Overactive Bladder Diagnosis and Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 76. Saudi Arabia Overactive Bladder Diagnosis and Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 77. South Africa Overactive Bladder Diagnosis and Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 78. Manufacturing Cost Structure Analysis of Overactive Bladder Diagnosis and Treatment in 2021
Figure 79. Manufacturing Process Analysis of Overactive Bladder Diagnosis and Treatment
Figure 80. Overactive Bladder Diagnosis and Treatment Industrial Chain
Figure 81. Sales Channel: Direct Channel vs Indirect Channel
Figure 82. Methodology
Figure 83. Research Process and Data Source


*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • 痔診断＆治療のグローバル市場展望 2023年-2029年：硬化療法用インジェクタ、赤外線凝固装置、バイポーラプローブ、凍結療法装置、痔用レーザープローブ、その他
  • 世界の膀胱がん検出キット市場2022年：市場規模予測（～2028年）
  • 食物アレルギー診断治療の世界市場 2022年-2026年
  • 膀胱容量計カテーテルのグローバル市場展望 2023年-2029年：大人用、子供用
  • ポータブル超音波膀胱スキャナーのグローバル市場展望 2023年-2029年：2Dポータブル超音波膀胱スキャナー、3Dポータブル超音波膀胱スキャナー
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(GIR22NO19502 )"世界の過活動性膀胱診断及び治療法市場2022年：市場規模予測（～2028年）" (英文：Global Overactive Bladder Diagnosis and Treatment Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028)はGlobalInfoResearch社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。